Jyong Biotech Ltd. Ordinary Shares (MENS)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a margin of safety. Jyong Biotech does not yet fit that mold. It is a 27-employee biotech founded in 2002, developing plant-derived drugs for urinary conditions: Botreso for benign prostate hyperplasia/lower urinary tract symptoms, PCP for prostate cancer, and an interstitial cystitis program. The market values the whole company at $167.7 million as of the 2026-10-13 close of $2.04. On the numbers provided, the company lost money: EPS is $-0.06 and the P/E is -34.00, so there are no earnings to value. Revenue growth, profit growth, ROE, P/B, and D/E are not available, and there is no Lynch category because only zero years of filed results exist. The quality measures are poor: ROCE is -12.01%, Piotroski is 2/9, Altman Z is -1.45, and the FairStock Score is 20/100. A 52-week range of $1.43 to $63.00 tells me the shares have been extraordinarily volatile and are far below their high. In Graham terms, I cannot calculate a defensible intrinsic value from these figures. The upside rests entirely on clinical and regulatory success for the pipeline; the downside is that without revenue, profits, or a long filed history, the stock is a speculative bet on drug development. I would need audited revenue, cash burn, and trial data before treating this as an investment rather than a lottery ticket. Until then, the price may be low, but it is not demonstrably cheap.

In plain English: Jyong Biotech is a small healthcare company developing plant-derived drugs for urinary system problems such as prostate enlargement and bladder pain. The business looks weak right now: it is losing money, has very little reported financial history, and its financial-health scores are poor. At $2.04, the shares have collapsed from a 52-week high of $63.00, but with no profits or meaningful revenue figures, the price is hard to call cheap on the numbers alone.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer